Top

Open Access 23-04-2024 | Thrombosis | Research

Association of JAK2V617F allele burden and clinical correlates in polycythemia vera: a systematic review and meta-analysis

Authors: Chih-Cheng Chen, Justin L. Chen, Alex Jia-Hong Lin, Lennex Hsueh-Lin Yu, Hsin-An Hou

Abstract

Janus kinase 2 (JAK2) V617F mutation is present in most patients with polycythemia vera (PV). One persistently puzzling aspect unresolved is the association between JAK2V617F allele burden (also known as variant allele frequency) and the relevant clinical characteristics. Numerous studies have reported associations between allele burden and both hematologic and clinical features. While there are strong indications linking high allele burden in PV patients with symptoms and clinical characteristics, not all associations are definitive, and disparate and contradictory findings have been reported. Hence, this study aimed to synthesize existing data from the literature to better understand the association between JAK2V617F allele burden and relevant clinical correlates. Out of the 1,851 studies identified, 39 studies provided evidence related to the association between JAK2V617F allele burden and clinical correlates, and 21 studies were included in meta-analyses. Meta-analyses of correlation demonstrated that leucocyte and erythrocyte counts were significantly and positively correlated with JAK2V617F allele burden, whereas platelet count was not. Meta-analyses of standardized mean difference demonstrated that leucocyte and hematocrit were significantly higher in patients with higher JAK2V617F allele burden, whereas platelet count was significantly lower. Meta-analyses of odds ratio demonstrated that patients who had higher JAK2V617F allele burden had a significantly greater odds ratio for developing pruritus, splenomegaly, thrombosis, myelofibrosis, and acute myeloid leukemia. Our study integrates data from approximately 5,462 patients, contributing insights into the association between JAK2V617F allele burden and various hematological parameters, symptomatic manifestations, and complications. However, varied methods of data presentation and statistical analyses prevented the execution of high-quality meta-analyses.

Available only for authorised users

Baxter EJ, Scott LM, Campbell PJ et al (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders [published correction appears in Lancet. 2005 Jul 9–15;366(9480):122]. Lancet 365(9464):1054–1061. https://doi.org/10.1016/S0140-6736(05)71142-9CrossRefPubMed

Levine RL, Wadleigh M, Cools J et al (2005) Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7(4):387–397. https://doi.org/10.1016/j.ccr.2005.03.023CrossRefPubMed

Garçon L, Rivat C, James C et al (2006) Constitutive activation of STAT5 and Bcl-xL overexpression can induce endogenous erythroid colony formation in human primary cells. Blood 108(5):1551–1554. https://doi.org/10.1182/blood-2005-10-009514CrossRefPubMed

Kralovics R, Teo SS, Li S et al (2006) Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders. Blood 108(4):1377–1380. https://doi.org/10.1182/blood-2005-11-009605CrossRefPubMed

Rane SG, Reddy EP (2002) JAKs, STATs and Src kinases in hematopoiesis. Oncogene 21(21):3334–3358. https://doi.org/10.1038/sj.onc.1205398CrossRefPubMed

Akada H, Yan D, Zou H et al (2010) Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease. Blood 115(17):3589–3597. https://doi.org/10.1182/blood-2009-04-215848CrossRefPubMedPubMedCentral

Nangalia J, Green TR (2014) The evolving genomic landscape of myeloproliferative neoplasms. Hematol Am Soc Hematol Educ Program 2014(1):287–296. https://doi.org/10.1182/asheducation-2014.1.287Epub 2014 Nov 18. PMID: 25696868CrossRef

Scott LM, Tong W, Levine RL et al (2007) JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 356(5):459–468. https://doi.org/10.1056/NEJMoa065202CrossRefPubMedPubMedCentral

Alvarez-Larrán A, Bellosillo B, Pereira A et al (2014) JAK2V617F monitoring in polycythemia vera and essential thrombocythemia: clinical usefulness for predicting myelofibrotic transformation and thrombotic events. Am J Hematol 89(5):517–523. https://doi.org/10.1002/ajh.23676CrossRefPubMed

10.

Page MJ, McKenzie JE, Bossuyt PM et al (2021) Updating guidance for reporting systematic reviews: development of the PRISMA 2020 statement. J Clin Epidemiol 134:103–112. https://doi.org/10.1016/j.jclinepi.2021.02.003CrossRefPubMed

11.

Moola S, Munn Z, Tufanaru C, Aromataris E, Sears K, Sfetcu R, Currie M, Qureshi R, Mattis P, Lisy K, Mu P-F (2020) Chapter 7: Systematic reviews of etiology and risk. In: Aromataris E, Munn Z (Editors). JBI Manual for Evidence Synthesis. JBI, https://synthesismanual.jbi.global

12.

Bai J, Ai L, Zhang L, Yang FC, Zhou Y, Xue Y (2015) Incidence and risk factors for myelofibrotic transformation among 272 Chinese patients with JAK2-mutated polycythemia vera. Am J Hematol 90(12):1116–1121. https://doi.org/10.1002/ajh.24191CrossRefPubMed

13.

Barbui T, Carobbio A, Finazzi G et al (2011) Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3. Haematologica 96(2):315–318. https://doi.org/10.3324/haematol.2010.031070CrossRefPubMed

14.

Bellanné-Chantelot C, Chaumarel I, Labopin M et al (2006) Genetic and clinical implications of the Val617Phe JAK2 mutation in 72 families with myeloproliferative disorders. Blood 108(1):346–352. https://doi.org/10.1182/blood-2005-12-4852CrossRefPubMed

15.

Carobbio A, Finazzi G, Antonioli E et al (2009) JAK2V617F allele burden and thrombosis: a direct comparison in essential thrombocythemia and polycythemia vera. Exp Hematol 37(9):1016–1021. https://doi.org/10.1016/j.exphem.2009.06.006CrossRefPubMedPubMedCentral

16.

Čokić VP, Mitrović-Ajtić O, Beleslin-Čokić BB et al (2015) Proinflammatory cytokine IL-6 and JAK-STAT signaling pathway in Myeloproliferative Neoplasms. Mediators Inflamm 2015:453020. https://doi.org/10.1155/2015/453020CrossRefPubMedPubMedCentral

17.

Coucelo M, Caetano G, Sevivas T et al (2014) JAK2V617F allele burden is associated with thrombotic mechanisms activation in polycythemia vera and essential thrombocythemia patients. Int J Hematol 99(1):32–40. https://doi.org/10.1007/s12185-013-1475-9CrossRefPubMed

18.

Edahiro Y, Morishita S, Takahashi K et al (2014) JAK2V617F mutation status and allele burden in classical Ph-negative myeloproliferative neoplasms in Japan. Int J Hematol 99(5):625–634. https://doi.org/10.1007/s12185-014-1567-1CrossRefPubMed

19.

Ferdowsi S, Atarodi K, Amirizadeh N et al (2015) Expression analysis of microRNA-125 in patients with polycythemia vera and essential thrombocythemia and correlation with JAK2 allele burden and laboratory findings. Int J Lab Hematol 37(5):661–667. https://doi.org/10.1111/ijlh.12381CrossRefPubMed

20.

Ferdowsi S, Ghaffari SH, Amirizadeh N et al (2016) JAK2V617F Allele Burden Measurement in Peripheral blood of Iranian patients with myeloproliferative neoplasms and effect of Hydroxyurea on JAK2V617F Allele Burden. Int J Hematol Oncol Stem Cell Res 10(2):70–78PubMedPubMedCentral

21.

Gangat N, Strand JJ, Lasho TL, Li CY, Pardanani A, Tefferi A (2008) Pruritus in Polycythemia vera is associated with a lower risk of arterial thrombosis. Am J Hematol 83(6):451–453. https://doi.org/10.1002/ajh.21156CrossRefPubMed

22.

Gangat N, Strand J, Lasho TL et al (2008) Cytogenetic studies at diagnosis in polycythemia vera: clinical and JAK2V617F allele burden correlates. Eur J Haematol 80(3):197–200. https://doi.org/10.1111/j.1600-0609.2007.01003.xCrossRefPubMed

23.

Gangemi S, Allegra A, Pace E et al (2012) Evaluation of interleukin-23 plasma levels in patients with polycythemia vera and essential thrombocythemia. Cell Immunol 278(1–2):91–94. https://doi.org/10.1016/j.cellimm.2012.07.003CrossRefPubMed

24.

Ha JS, Kim YK, Jung SI, Jung HR, Chung IS (2012) Correlations between Janus kinase 2 V617F allele burdens and clinicohematologic parameters in myeloproliferative neoplasms. Ann Lab Med 32(6):385–391. https://doi.org/10.3343/alm.2012.32.6.385CrossRefPubMedPubMedCentral

25.

Hu L, Pu L, Ding Y et al (2017) Relationship between JAK2V617F mutation, allele burden and coagulation function in Ph-negative myeloproliferative neoplasms. Hematology 22(6):354–360. https://doi.org/10.1080/10245332.2016.1267830CrossRefPubMed

26.

Koren-Michowitz M, Landman J, Cohen Y et al (2012) JAK2V617F allele burden is associated with transformation to myelofibrosis. Leuk Lymphoma 53(11):2210–2213. https://doi.org/10.3109/10428194.2012.682308CrossRefPubMed

27.

Larsen TS, Pallisgaard N, Møller MB, Hasselbalch HC (2007) The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis–impact on disease phenotype. Eur J Haematol 79(6):508–515. https://doi.org/10.1111/j.1600-0609.2007.00960.xCrossRefPubMed

28.

Lee AJ, Kim SG, Nam JY, Yun J, Ryoo HM, Bae SH (2021) Clinical features and outcomes of JAK2 V617F-positive polycythemia vera and essential thrombocythemia according to the JAK2 V617F allele burden. Blood Res 56(4):259–265. https://doi.org/10.5045/br.2021.2021089CrossRefPubMedPubMedCentral

29.

Lekovic D, Gotic M, Skoda R et al (2017) Bone marrow microvessel density and plasma angiogenic factors in myeloproliferative neoplasms: clinicopathological and molecular correlations. Ann Hematol 96(3):393–404. https://doi.org/10.1007/s00277-016-2890-9CrossRefPubMed

30.

Malak S, Labopin M, Saint-Martin C, Bellanne-Chantelot C, Najman A, French Group of Familial Myeloproliferative Disorders (2012) Long term follow up of 93 families with myeloproliferative neoplasms: life expectancy and implications of JAK2V617F in the occurrence of complications. Blood Cells Mol Dis 49(3–4):170–176. https://doi.org/10.1016/j.bcmd.2012.06.004CrossRefPubMed

31.

Maslah N, Ravdan O, Drevon L et al (2022) Revisiting diagnostic performances of serum erythropoïetin level and JAK2 mutation for polycythemias: analysis of a cohort of 1090 patients with red cell mass measurement. Br J Haematol 196(3):676–680. https://doi.org/10.1111/bjh.17848CrossRefPubMed

32.

Moliterno AR, Williams DM, Rogers O, Isaacs MA, Spivak JL (2008) Phenotypic variability within the JAK2 V617F-positive MPD: roles of progenitor cell and neutrophil allele burdens. Exp Hematol 36(11):1480–1486. https://doi.org/10.1016/j.exphem.2008.05.006CrossRefPubMedPubMedCentral

33.

Okabe M, Yamaguchi H, Usuki K et al (2016) Clinical features of Japanese polycythemia vera and essential thrombocythemia patients harboring CALR, JAK2V617F, JAK2Ex12del, and MPLW515L/K mutations. Leuk Res 40:68–76. https://doi.org/10.1016/j.leukres.2015.11.002CrossRefPubMed

34.

Passamonti F, Rumi E, Pietra D et al (2010) A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. Leukemia 24(9):1574–1579. https://doi.org/10.1038/leu.2010.148CrossRefPubMed

35.

Payzin KB, Savasoglu K, Alacacioglu I et al (2014) JAK2 V617F mutation status of 232 patients diagnosed with chronic myeloproliferative neoplasms. Clin Lymphoma Myeloma Leuk 14(6):525–533. https://doi.org/10.1016/j.clml.2014.02.013CrossRefPubMed

36.

Pieri L, Bogani C, Guglielmelli P et al (2009) The JAK2V617 mutation induces constitutive activation and agonist hypersensitivity in basophils from patients with polycythemia vera. Haematologica 94(11):1537–1545. https://doi.org/10.3324/haematol.2009.007047CrossRefPubMedPubMedCentral

37.

Popova-Labachevska M, Panovska-Stavridis I, Eftimov A et al (2019) Evaluation of the JAK2V617F mutational burden in patients with Philadelphia chromosome negative myeloproliferative neoplasms: a single-center experience. Balkan J Med Genet 22(2):31–36 Published 2019 Dec 21. https://doi.org/10.2478/bjmg-2019-0021CrossRefPubMedPubMedCentral

38.

Ruella M, Salmoiraghi S, Risso A et al (2013) Telomere shortening in Ph-negative chronic myeloproliferative neoplasms: a biological marker of polycythemia vera and myelofibrosis, regardless of hydroxycarbamide therapy. Exp Hematol 41(7):627–634. https://doi.org/10.1016/j.exphem.2013.03.007CrossRefPubMed

39.

Sacco M, Ranalli P, Lancellotti S et al (2020) Increased von Willebrand factor levels in polycythemia vera and phenotypic differences with essential thrombocythemia. Res Pract Thromb Haemost 4(3):413–421 Published 2020 Feb 28. https://doi.org/10.1002/rth2.12315CrossRefPubMedPubMedCentral

40.

Sazawal S, Singh K, Chhikara S, Chaubey R, Mahapatra M, Saxena R (2019) Influence of JAK2V617F allele burden on clinical phenotype of polycythemia vera patients: a study from India. South Asian J Cancer 8(2):127–129. https://doi.org/10.4103/sajc.sajc_161_18CrossRefPubMedPubMedCentral

41.

Silver RT, Vandris K, Wang YL et al (2011) JAK2(V617F) allele burden in polycythemia vera correlates with grade of myelofibrosis, but is not substantially affected by therapy. Leuk Res 35(2):177–182. https://doi.org/10.1016/j.leukres.2010.06.017CrossRefPubMed

42.

Stein BL, Rademaker A, Spivak JL, Moliterno AR (2011) Gender and vascular complications in the JAK2 V617F-Positive myeloproliferative neoplasms. Thrombosis 2011:874146. https://doi.org/10.1155/2011/874146CrossRefPubMedPubMedCentral

43.

Stein BL, Saraf S, Sobol U et al (2013) Age-related differences in disease characteristics and clinical outcomes in polycythemia vera. Leuk Lymphoma 54(9):1989–1995. https://doi.org/10.3109/10428194.2012.759656CrossRefPubMed

44.

Tefferi A, Strand JJ, Lasho TL et al (2007) Bone marrow JAK2V617F allele burden and clinical correlates in polycythemia vera. Leukemia 21(9):2074–2075. https://doi.org/10.1038/sj.leu.2404724CrossRefPubMed

45.

Vannucchi AM, Antonioli E, Guglielmelli P et al (2007) Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden. Leukemia 21(9):1952–1959. https://doi.org/10.1038/sj.leu.2404854CrossRefPubMed

46.

Vannucchi AM, Antonioli E, Guglielmelli P et al (2007) Clinical profile of homozygous JAK2 617V > F mutation in patients with polycythemia vera or essential thrombocythemia. Blood 110(3):840–846. https://doi.org/10.1182/blood-2006-12-064287CrossRefPubMed

47.

Zhao S, Zhang X, Xu Y et al (2016) Impact of JAK2V617F mutation burden on Disease phenotype in Chinese patients with JAK2V617F-positive Polycythemia Vera (PV) and essential thrombocythemia (ET). Int J Med Sci 13(1):85–91 Published 2016 Jan 25. https://doi.org/10.7150/ijms.10539CrossRefPubMedPubMedCentral

48.

Zhou J, Ye Y, Zeng S et al (2013) Impact of JAK2 V617F mutation on hemogram variation in patients with non-reactive elevated platelet counts. PLoS ONE 8(2):e57856. https://doi.org/10.1371/journal.pone.0057856CrossRefPubMedPubMedCentral

49.

Guglielmelli P, Loscocco GG, Mannarelli C et al (2021) JAK2V617F variant allele frequency > 50% identifies patients with polycythemia vera at high risk for venous thrombosis. Blood Cancer J 11(12):199 Published 2021 Dec 11. https://doi.org/10.1038/s41408-021-00581-6CrossRefPubMedPubMedCentral

50.

Alvarez-Larrán A, Angona A, Ancochea A et al (2016) Masked polycythaemia vera: presenting features, response to treatment and clinical outcomes. Eur J Haematol 96(1):83–89PubMedCrossRef

51.

Alvarez-Larrán A, Senín A, Fernández-Rodríguez C et al (2017) Impact of genotype on leukaemic transformation in polycythaemia vera and essential thrombocythaemia. Br J Haematol 178(5):764–771. https://doi.org/10.1111/bjh.14762CrossRefPubMed

52.

Ancochea À, Álvarez-Larrán A, Morales‐Indiano C et al (2014) The role of serum erythropoietin level and jak2 v617f allele burden in the diagnosis of polycythaemia vera. Br J Haematol 167(3):411–417PubMedCrossRef

53.

Andersen CL, Bjørn ME, McMullin MF et al (2014) Circulating YKL-40 in patients with essential thrombocythemia and polycythemia vera treated with the novel histone deacetylase inhibitor vorinostat. Leuk Res 38(7):816–821PubMedCrossRef

54.

Andréasson B, Pettersson H, Wasslavik C, Johansson P, Palmqvist L, Asp J (2020) ASXL1 mutations, previous vascular complications and age at diagnosis predict survival in 85 WHO-defined polycythaemia vera patients. Br J Haematol 189(5):913–919PubMedCrossRef

55.

Barbui T, Thiele J, Passamonti F et al (2012) Initial bone marrow reticulin fibrosis in polycythemia vera exerts an impact on clinical outcome. Blood 119(10):2239–2241PubMedCrossRef

56.

Barbui T, Vannucchi AM, Finazzi G et al (2017) A reappraisal of the benefit-risk profile of hydroxyurea in polycythemia vera: a propensity‐matched study. Am J Hematol 92(11):1131–1136PubMedCrossRef

57.

Barosi G (2018) Spleen in myeloproliferative neoplasms. Hemasphere 2(Suppl 2):173–174 Published 2018 Jun 11. https://doi.org/10.1097/HS9.0000000000000115CrossRefPubMedCentral

58.

Benati M, Montagnana M, Danese E et al (2015) Role of JAK2 V617F mutation and aberrant expression of microRNA-143 in myeloproliferative neoplasms. Clin Chem Lab Med (CCLM). ;53(7)

59.

Benton CB, Boddu PC, DiNardo CD et al (2019) Janus kinase 2 variants associated with the transformation of myeloproliferative neoplasms into acute myeloid leukemia. Cancer 125(11):1855–1866. https://doi.org/10.1002/cncr.31986CrossRefPubMed

60.

Bertozzi I, Bogoni G, Biagetti G et al (2017) Thromboses and hemorrhages are common in MPN patients with high JAK2V617F allele burden. Ann Hematol 96(8):1297–1302PubMedCrossRef

61.

Borowczyk M, Wojtaszewska M, Lewandowski K et al (2015) The JAK2 V617F mutational status and allele burden may be related with the risk of venous thromboembolic events in patients with Philadelphia-negative myeloproliferative neoplasms. Thromb Res 135(2):272–280PubMedCrossRef

62.

Chang H, Shih L, Michelson AD et al (2013) Clinical and Laboratory significance of defective P2Y < sub > 12 pathway function in patients with myeloproliferative neoplasms: a pilot study. Acta Haematol 130(3):181–187PubMedCrossRef

63.

Coltoff A, Mesa R, Gotlib J et al (2020) Real-world outcomes of Ruxolitinib Treatment for Polycythemia Vera. Clin Lymphoma Myeloma Leuk 20(10):697–703e1. https://doi.org/10.1016/j.clml.2020.05.019CrossRefPubMedPubMedCentral

64.

Crisà E, Cerrano M, Beggiato E et al (2017) Can pegylated interferon improve the outcome of polycythemia vera patients? J Hematol Oncol 10(1):15. https://doi.org/10.1186/s13045-017-0395-1. Published 2017 Jan 13CrossRefPubMedPubMedCentral

65.

Debureaux P, Cassinat B, Soret-Dulphy J et al (2020) Molecular profiling and risk classification of patients with myeloproliferative neoplasms and splanchnic vein thromboses. Blood Adv 4(15):3708–3715PubMedPubMedCentralCrossRef

66.

Gangaraju R, Song J, Kim SJ et al (2020) Thrombotic, inflammatory, and HIF-regulated genes and thrombosis risk in polycythemia vera and essential thrombocythemia. Blood Adv 4(6):1115–1130PubMedPubMedCentralCrossRef

67.

Garcia-Gisbert N, Fernández-Ibarrondo L, Fernández-Rodríguez C et al (2021) Circulating cell-free DNA improves the molecular characterisation of Ph-negative myeloproliferative neoplasms. Br J Haematol 192(2):300–309. https://doi.org/10.1111/bjh.17087CrossRefPubMed

68.

Garcia-Gisbert N, Camacho L, Fernández-Ibarrondo L et al (2020) Analysis of saliva samples and cluster of differentiation 3 (CD3) + lymphocytes as a source of germline DNA in myeloproliferative neoplasms. Br J Haematol 189(5):e204–e207. https://doi.org/10.1111/bjh.16624CrossRefPubMed

69.

Giona F, Teofili L, Moleti ML et al (2012) Thrombocythemia and polycythemia in patients younger than 20 years at diagnosis: clinical and biologic features, treatment, and long-term outcome. Blood 119(10):2219–2227PubMedCrossRef

70.

Gupta V, Kennedy JA, Capo-Chichi JM et al (2021) Genetic factors rather than blast reduction determine outcomes of allogeneic HCT in BCR-ABL-negative MPN in blast phase [published correction appears in Blood Adv. ;5(11):2518]. Blood Adv. 2020;4(21):5562–5573. https://doi.org/10.1182/bloodadvances.2020002727

71.

Guru SA, Sumi MP, Mir R et al (2020) Ectopic PD-L1 expression in JAK2 (V617F) myeloproliferative neoplasm patients is mediated via increased activation of STAT3 and STAT5. Hum Cell 33(4):1099–1111PubMedCrossRef

72.

Guy A, Danaee A, Paschalaki K et al (2020) Absence of JAK2V617F mutated endothelial colony-forming cells in patients with JAK2V617F myeloproliferative neoplasms and splanchnic vein thrombosis. Hemasphere 4(3):e364 Published 2020 May 5. https://doi.org/10.1097/HS9.0000000000000364CrossRefPubMedPubMedCentral

73.

Ha JS, Jeon DS, Kim JR, Ryoo NH, Suh JS (2014) Analysis of the Ten-Eleven translocation 2 (TET2) gene mutation in myeloproliferative neoplasms. Ann Clin Lab Sci 44(2):173–179

74.

Heibl S, Gisslinger B, Jäger E et al (2020) Clinical, hematologic, biologic and molecular characteristics of patients with myeloproliferative neoplasms and a Chronic Myelomonocytic Leukemia-Like phenotype. Cancers (Basel) 12(7):1891PubMedCrossRef

75.

Hussein K, Bock O, Theophile K et al (2009) JAK2(V617F) allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis. Exp Hematol 37(10):1186–1193e7PubMedCrossRef

76.

Karantanos T, Chaturvedi S, Braunstein EM et al (2020) Sex determines the presentation and outcomes in MPN and is related to sex-specific differences in the mutational burden. Blood Adv 4(12):2567–2576PubMedPubMedCentralCrossRef

77.

Kissova J, Ovesna P, Bulikova A, Zavřelova J, Penka M (2015) Increasing procoagulant activity of circulating microparticles in patients with Philadelphia-negative myeloproliferative neoplasms: a single-centre experience. Blood Coagul Fibrinolysis 26(4):448–453PubMedCrossRef

78.

Kondo T, Okuno N, Naruse H et al (2008) Validation of the revised 2008 WHO diagnostic criteria in 75 suspected cases of myeloproliferative neoplasm. Leuk Lymphoma 49(9):1784–1791PubMedCrossRef

79.

Koschmieder S, Chatain N (2018) Inflammation and anti-inflammatory approaches in myeloproliferative neoplasm. Hemasphere 2(Suppl 2):143–145 Published 2018 Jun 11. https://doi.org/10.1097/HS9.0000000000000106CrossRefPubMedCentral

80.

Kovacsovics-Bankowski M, Kelley TW, Efimova O et al (2015) Changes in peripheral blood lymphocytes in polycythemia vera and essential thrombocythemia patients treated with pegylated-interferon alpha and correlation with JAK2V617F allelic burden. Exp Hematol Oncol 5:28PubMedCrossRef

81.

Kurtovic-Kozaric A, Islamagic E, Komic H et al (2020) The effects of mutational profiles on phenotypic presentation of myeloproliferative neoplasm subtypes in Bosnia: 18 year follow-up. Bosn J Basic Med Sci 20(2):236–247PubMedPubMedCentral

82.

Larsen TS, Møller MB, de Stricker K et al (2009) Minimal residual disease and normalization of the bone marrow after long-term treatment with alpha-interferon2b in polycythemia vera. A report on molecular response patterns in seven patients in sustained complete hematological remission. Hematology 14(6):331–334PubMedCrossRef

83.

Larsen TS, Pallisgaard N, Møller MB, Hasselbalch HC (2008) High prevalence of arterial thrombosis in JAK2 mutated essential thrombocythaemia: independence of the V617F allele burden. Hematology 13(2):71–76PubMedCrossRef

84.

Larsen TS, Pallisgaard N, Møller MB, Hasselbalch HC (2008) Quantitative assessment of the JAK2 V617F allele burden: equivalent levels in peripheral blood and bone marrow. Leukemia 22(1):194–195PubMedCrossRef

85.

Limvorapitak W, Parker J, Hughesman C, McNeil K, Foltz L, Karsan A (2020) No differences in outcomes between JAK2 V617F–Positive patients with variant allele fraction < 2% versus 2–10%: a 6-Year Province-wide retrospective analysis. Clin Lymphoma Myeloma Leuk 20(9):e569–e578PubMedCrossRef

86.

Luque Paz D, Chauveau A, Boyer F et al (2017) Sequential analysis of 18 genes in polycythemia vera and essential thrombocythemia reveals an association between mutational status and clinical outcome. Genes Chromosomes Cancer 56(5):354–362PubMedCrossRef

87.

Lussana F, Carobbio A, Salmoiraghi S et al (2017) Driver mutations (JAK2V617F, MPLW515L/K or CALR), pentraxin-3 and C-reactive protein in essential thrombocythemia and polycythemia vera. J Hematol Oncol 10(1):54PubMedPubMedCentralCrossRef

88.

Makarik TV, Abdullaev AO, Nikulina EE et al (2021) Low JAK2 V617F allele Burden in Ph-Negative chronic myeloproliferative neoplasms is Associated with additional CALR or MPL gene mutations. Genes (Basel) 12(4):559PubMedCrossRef

89.

Mattar MM, Nassef S, El Husseiny NM et al (2019) Incidence of silent thrombosis in patients younger than 60 years with myeloproliferative neoplasms: single-center Egyptian study. Clin Lymphoma Myeloma Leuk 19(8):e425–e429PubMedCrossRef

90.

Mattar MM, Morad MA, El Husseiny NM, Ali NH, El Demerdash DM (2016) Correlation between JAK2 allele burden and pulmonary arterial hypertension and hematological parameters in Philadelphia negative JAK2 positive myeloproliferative neoplasms. An Egyptian experience. Ann Hematol 95(10):1611–1616PubMedCrossRef

91.

Milosevic Feenstra JD, Jäger R, Schischlik F et al (2022) PD-L1 overexpression correlates with JAK2‐V617F mutational burden and is associated with 9p uniparental disomy in myeloproliferative neoplasms. Am J Hematol 97(4):390–400PubMedPubMedCentralCrossRef

92.

Misawa K, Yasuda H, Araki M et al (2018) Mutational subtypes of JAK2 and CALR correlate with different clinical features in Japanese patients with myeloproliferative neoplasms. Int J Hematol 107(6):673–680PubMedCrossRef

93.

Moia R, Cittone MG, Boggione P et al (2021) Stiffer spleen predicts higher bone marrow fibrosis and higher JAK2 allele Burden in patients with myeloproliferative neoplasms. Front Oncol 11:777730PubMedPubMedCentralCrossRef

94.

Nangalia J, Bench AJ, Green AR, Godfrey AL (2019) Myeloproliferative neoplasms. In Molecular Hematology (eds D. Provan and J. Gribben). https://doi.org/10.1002/9781119252863.ch7

95.

Ok CY, Trowell KT, Parker KG et al (2021) Chronic myeloid neoplasms harboring concomitant mutations in myeloproliferative neoplasm driver genes (JAK2/MPL/CALR) and SF3B1. Mod Pathol 34(1):20–31. https://doi.org/10.1038/s41379-020-0624-yCrossRefPubMed

96.

Panova-Noeva M, Marchetti M, Spronk HM et al (2011) Platelet-induced thrombin generation by the calibrated automated thrombogram assay is increased in patients with essential thrombocythemia and polycythemia vera. Am J Hematol 86(4):337–342PubMedCrossRef

97.

Park SH, Chi HS, Cho YU, Jang S, Park CJ (2013) The allele burden of JAK2 V617F can aid in differential diagnosis of Philadelphia chromosome-negative myeloproliferative neoplasm. Blood Res 48(2):128–132PubMedPubMedCentralCrossRef

98.

Pearson S, Blance R, Somervaille TCP, Whetton AD, Pierce A (2019) AXL Inhibition extinguishes primitive JAK2 mutated myeloproliferative neoplasm progenitor cells. Hemasphere 3(3):e233 Published 2019 Jun 4. https://doi.org/10.1097/HS9.0000000000000233CrossRefPubMedPubMedCentral

99.

Perricone M, Polverelli N, Martinelli G et al (2017) The relevance of a low JAK2V617F allele burden in clinical practice: a monocentric study. Oncotarget 8(23):37239–37249PubMedPubMedCentralCrossRef

100.

Randi ML, Ruzzon E, Tezza F et al (2011) JAK2V617F mutation is common in old patients with polycythemia vera and essential thrombocythemia. Aging Clin Exp Res 23(1):17–21PubMedCrossRef

101.

Risum M, Madelung A, Bondo H et al (2011) The JAK2V617F allele burden and STAT3- and STAT5 phosphorylation in myeloproliferative neoplasms: early prefibrotic myelofibrosis compared with essential thrombocythemia, polycythemia vera and myelofibrosis. APMIS 119(8):498–504PubMedCrossRef

102.

Rotunno G, Pacilli A, Artusi V et al (2016) Epidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thrombocythemia myelofibrosis: a study on 359 patients of the AGIMM group. Am J Hematol 91(7):681–686PubMedCrossRef

103.

Sant’Antonio E, Guglielmelli P, Pieri L et al (2020) Splanchnic vein thromboses associated with myeloproliferative neoplasms: an international, retrospective study on 518 cases. Am J Hematol 95(2):156–166PubMedCrossRef

104.

Schischlik F, Jäger R, Rosebrock F et al (2019) Mutational landscape of the transcriptome offers putative targets for immunotherapy of myeloproliferative neoplasms. Blood 134(2):199–210. https://doi.org/10.1182/blood.2019000519CrossRefPubMedPubMedCentral

105.

Schino M, Fiorentino V, Rossi E et al (2021) Bone marrow megakaryocytic activation predicts fibrotic evolution of Philadelphia-negative myeloproliferative neoplasms. Haematologica 106(12):3162–3169PubMedCrossRef

106.

Shirane S, Araki M, Morishita S et al (2015) Consequences of the JAK2V617F allele burden for the prediction of transformation into myelofibrosis from polycythemia vera and essential thrombocythemia. Int J Hematol 101(2):148–153PubMedCrossRef

107.

Singdong R, Siriboonpiputtana T, Chareonsirisuthigul T et al (2016) Characterization and prognosis significance of JAK2 (V617F), MPL, and CALR mutations in Philadelphia-Negative myeloproliferative neoplasms. Asian Pac J Cancer Prev 17(10):4647–4653PubMedPubMedCentral

108.

Soderquist CR, Ewalt MD, Czuchlewski DR et al (2018) Myeloproliferative neoplasms with concurrent BCR-ABL1 translocation and JAK2 V617F mutation: a multi-institutional study from the bone marrow pathology group. Mod Pathol 31(5):690–704. https://doi.org/10.1038/modpathol.2017.182CrossRefPubMedPubMedCentral

109.

Sørensen AL, Bjørn ME, Riley CH et al (2019) B-cell frequencies and immunoregulatory phenotypes in myeloproliferative neoplasms: influence of ruxolitinib, interferon-α2, or combination treatment. Eur J Haematol 103(4):351–361PubMedCrossRef

110.

Sørensen AL, Knudsen TA, Skov V et al (2021) Smoking impairs molecular response, and reduces overall survival in patients with chronic myeloproliferative neoplasms: a retrospective cohort study. Br J Haematol 193(1):83–92. https://doi.org/10.1111/bjh.17130CrossRefPubMed

111.

Soudet S, Le Roy G, Cadet E et al (2022) JAK2 allele burden is correlated with a risk of venous but not arterial thrombosis. Thromb Res 211:1–5PubMedCrossRef

112.

Spivak JL, Considine M, Williams DM et al (2014) Two clinical phenotypes in polycythemia vera. N Engl J Med 371(9):808–817PubMedPubMedCentralCrossRef

113.

Stein BL, Rademaker A, Spivak JL, Moliterno AR (2011) Gender and vascular complications in the JAK2 V617F-Positive myeloproliferative neoplasms. Thrombosis 2011:874146PubMedPubMedCentralCrossRef

114.

Tefferi A, Sirhan S, Lasho TL et al (2005) Concomitant neutrophil JAK2V617F mutation screening and PRV-1 expression analysis in myeloproliferative disorders and secondary polycythaemia. Br J Haematol 131(2):166–171PubMedCrossRef

115.

Trifa AP, Bănescu C, Voina CM et al (2018) Modest contribution of JAK2 V617F allele burden to the occurrence of major thrombosis in polycthemia vera and essential thrombocythemia. Blood Cells Mol Dis 73:45–46PubMedCrossRef

116.

Trifa AP, Cucuianu A, Petrov L et al (2010) The G allele of the JAK2 rs10974944 SNP, part of JAK2 46/1 haplotype, is strongly associated with JAK2 V617F-positive myeloproliferative neoplasms. Ann Hematol 89(10):979–983PubMedCrossRef

117.

Utke Rank C, Weis Bjerrum O, Larsen TS et al (2016) Minimal residual disease after long-term interferon-alpha2 treatment: a report on hematological, molecular and histomorphological response patterns in 10 patients with essential thrombocythemia and polycythemia vera. Leuk Lymphoma 57(2):348–354PubMedCrossRef

118.

Vadikolia C, Tsatalas C, Anagnostopoulos K et al (2011) Proteolytic matrix metallopeptidases and inhibitors in BCR-ABL1-Negative myeloproliferative neoplasms: correlation with JAK2 < sup > V617F mutation status. Acta Haematol 126(1):54–62PubMedCrossRef

119.

Yang N, Park S, Cho M et al (2018) GATA1 expression in BCR/ABL1-negative myeloproliferative neoplasms. Ann Lab Med 38(4):296–305PubMedPubMedCentralCrossRef

120.

Yoo E, Park K, Won H et al (2016) Genetic characteristics of Polycythemia Vera and essential thrombocythemia in Korean patients. Clin Lab Anal 30(6):1061–1070CrossRef

121.

Zangari M, Fink L, Tolomelli G et al (2013) Could hypoxia increase the prevalence of thrombotic complications in polycythemia vera? Blood Coagul Fibrinolysis 24(3):311–316PubMedPubMedCentralCrossRef

122.

Zhang Y, Zhou Y, Wang Y et al (2020) Thrombosis among 1537 patients with JAK2V617F-mutated myeloproliferative neoplasms: risk factors and development of a predictive model. Cancer Med 9(6):2096–2105PubMedPubMedCentralCrossRef

123.

Ianotto JC, Chauveau A, Boyer-Perrard F et al (2018) Benefits and pitfalls of pegylated interferon-α2a therapy in patients with myeloproliferative neoplasm-associated myelofibrosis: a French Intergroup of Myeloproliferative neoplasms (FIM) study. Haematologica 103(3):438–446. https://doi.org/10.3324/haematol.2017.181297CrossRefPubMedPubMedCentral

124.

Kiladjian JJ, Klade C, Georgiev P et al (2022) Long-term outcomes of polycythemia vera patients treated with ropeginterferon Alfa-2b. Leukemia 36(5):1408–1411. https://doi.org/10.1038/s41375-022-01528-xCrossRefPubMedPubMedCentral

125.

de Oliveira RD, Soret Dulphy J, Zhao LP et al (2020) Interferon-Alpha (IFN) Therapy discontinuation is feasible in Myeloproliferative Neoplasm (MPN) patients with complete hematological remission. Blood 136:S1:35–36. https://doi.org/10.1182/blood-2020-141223CrossRef

126.

Harrison CN, Nangalia J, Boucher R et al (2023) Ruxolitinib Versus Best available therapy for Polycythemia Vera intolerant or resistant to Hydroxycarbamide in a Randomized Trial. J Clin Oncol 41(19):3534–3544. https://doi.org/10.1200/JCO.22.01935CrossRefPubMedPubMedCentral

127.

Gisslinger H, Klade C, Georgiev P et al (2023) Event-free survival in patients with polycythemia vera treated with ropeginterferon alfa-2b versus best available treatment. Leukemia 37(10):2129–2132. https://doi.org/10.1038/s41375-023-02008-6CrossRefPubMedPubMedCentral

128.

Moliterno AR, Kaizer H, Reeves BN (2023) JAK2 V617F allele burden in polycythemia vera: burden of proof. Blood 141(16):1934–1942. https://doi.org/10.1182/blood.2022017697CrossRefPubMedPubMedCentral

129.

Mesa RA, Miller CB, Thyne M et al (2017) Differences in treatment goals and perception of symptom burden between patients with myeloproliferative neoplasms (MPNs) and hematologists/oncologists in the United States: findings from the MPN Landmark survey. Cancer 123(3):449–458. https://doi.org/10.1002/cncr.30325CrossRefPubMed

130.

Tsai TH, Yu LH, Yu MS et al (2023) Real-world patient characteristics and treatment patterns of polycythemia vera in Taiwan between 2016 and 2017: a nationwide cross-sectional study. Ther Adv Hematol 14:20406207231179331 Published 2023 Jun 15. https://doi.org/10.1177/20406207231179331CrossRefPubMedPubMedCentral

131.

Parasuraman S, Yu J, Paranagama D et al (2018) Cytoreductive treatment patterns among US veterans with polycythemia vera. BMC Cancer 18:528–018PubMedPubMedCentralCrossRef

Title: Association of JAK2V617F allele burden and clinical correlates in polycythemia vera: a systematic review and meta-analysis
Authors: Chih-Cheng Chen
Justin L. Chen
Alex Jia-Hong Lin
Lennex Hsueh-Lin Yu
Hsin-An Hou
Publication date: 23-04-2024
Publisher: Springer Berlin Heidelberg
Keywords: Thrombosis
Pruritus
Published in: Annals of Hematology
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI: https://doi.org/10.1007/s00277-024-05754-4

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage